Sofiya Vinogradova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Sofiya Vinogradova has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- I. A. Balazs
National research center “Kurchatov Institute
4 shared publications - Konstantin Severinov
Institute of Gene Biology, Russian Academy of Sciences, Moscow, 119334, Russia
4 shared publications - Olga Musharova
Skolkovo Institute of Science and Technology
4 shared publications - Yunna Sergeevna Petrusenko
M.M. Shemyakin and Yu.A. Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences
2 shared publications Alexander Ernst
Clinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center, Heidelberg, Germany
1 shared publicationChin Leng Tan
Clinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center, Heidelberg, Germany
1 shared publication
Latest Publications
- 8 December 2025
- Published by Ob'edinennaya Redakcya OOO in Molecular Genetics Microbiology and Virology (Russian version)
- Vol. 43 (4) , 79-84
Studying the mechanisms of prespacer 3’-end formation during CRISPR adaptation via simultaneous gene repression using dCas9
Introduction. Bacteria are capable of integrating a portion of the genetic material of an invading infectious agent as a spacer into the CRISPR array. This process is called CRISPR adaptation and is necessary for bacteria to adequately respond to the same infectious agent in the future. The molecular mechanisms of CRISPR adaptation remain unclear, particularly the role of extra-CRISPR-Cas components in bacteria during prespacer generation and spacer acquisition. In this study, we developed an approach to identifying nucleases responsible for the formation of prespacer 3’-ends in vivo. Materials and methods. We generated a genetic construct based on the pBR322 plasmid vector with gRNAs targeting the genes encoding cellular exonucleases with 3’-5’ activity in E. coli. This genetic construct and the pdCas9 plasmid were transformed into KD403 cells. The level of primed CRISPR adaptation was assessed using PCR and sequencing. The structure of the 3' ends of the prespacers was assessed using the FragSeq short-fragment sequencing method using the Accel-NGS® 1S Plus DNA Library Kit, Swift biosciences (xGen™ ssDNA & Low-Input DNA Library Preparation Kit, IDT). Results. In the KD403 ΔrecB strain with suppressed nucleases, a reduction in primed adaptation was detected, but sequencing revealed no disruption of the 3’ ends of the spacer precursors. Conclusion. Our results contribute to the understanding of the molecular mechanisms of CRISPR adaptation, which may aid in the development of CRISPR-based approaches in medicine and agriculture in the future.
- 8 December 2025
- Published by Ob'edinennaya Redakcya OOO in Molecular Genetics Microbiology and Virology (Russian version)
- Vol. 43 (4) , 79-84
Studying the mechanisms of prespacer 3’-end formation during CRISPR adaptation via simultaneous gene repression using dCas9
Introduction. Bacteria are capable of integrating a portion of the genetic material of an invading infectious agent as a spacer into the CRISPR array. This process is called CRISPR adaptation and is necessary for bacteria to adequately respond to the same infectious agent in the future. The molecular mechanisms of CRISPR adaptation remain unclear, particularly the role of extra-CRISPR-Cas components in bacteria during prespacer generation and spacer acquisition. In this study, we developed an approach to identifying nucleases responsible for the formation of prespacer 3’-ends in vivo. Materials and methods. We generated a genetic construct based on the pBR322 plasmid vector with gRNAs targeting the genes encoding cellular exonucleases with 3’-5’ activity in E. coli. This genetic construct and the pdCas9 plasmid were transformed into KD403 cells. The level of primed CRISPR adaptation was assessed using PCR and sequencing. The structure of the 3' ends of the prespacers was assessed using the FragSeq short-fragment sequencing method using the Accel-NGS® 1S Plus DNA Library Kit, Swift biosciences (xGen™ ssDNA & Low-Input DNA Library Preparation Kit, IDT). Results. In the KD403 ΔrecB strain with suppressed nucleases, a reduction in primed adaptation was detected, but sequencing revealed no disruption of the 3’ ends of the spacer precursors. Conclusion. Our results contribute to the understanding of the molecular mechanisms of CRISPR adaptation, which may aid in the development of CRISPR-based approaches in medicine and agriculture in the future.
- 8 December 2025
- Published by Ob'edinennaya Redakcya OOO in Molecular Genetics Microbiology and Virology (Russian version)
- Vol. 43 (4) , 74-78
The role of intracellular nucleases in the correction of aberrant 5’-ends of prespacers in the E. Coli CRISPR-Cas I-E system
Introduction. Bacteria need CRISPR-Cas systems to form an adaptive immune response necessary for protection against infectious agents. In addition, in recent years, CRISPR-Cas systems have been actively studied in the context of the development of new methods for editing the genome, which have great potential in the development of new strategies in the fight against infectious and other diseases. The mechanism of formation of bacterial adaptive immunity using CRISPR-Cas systems is in the ability of bacteria to integrate fragments of foreign DNA (for example, bacteriophage DNA), which are called spacers, into their genome, which further allows bacteria to recognize and protect themselves from these infectious agents. However, not much is known about the molecular mechanisms of this process, which limits a lot the ability of scientists to understand and apply CRISPR-Cas systems. In particular, the question of the role of non-CRISPR-Cas components of bacterial cells in the formation of CRISPR adaptation remains open. Such components, for example, are intracellular nucleases, which play a role in the CRISPR adaptation process we aimed to study within our scientific project. It has been previously proven that nucleases are involved in the preparation of a foreign DNA fragment for insertion into the bacterial DNA (CRISPR cassette), which is necessary to ensure CRISPR adaptation –it has to have the certain structure and the correct length. It has been shown that aberrations in the formation of the 5' ends of prespacers do not affect their incorporation into the CRISPR cassette and the efficiency of adaptation. Material and methods. Two mutant strains, Bl21-AI Δxni (Flap endonuclease ExoIX) and Bl21-AI ΔpolA exo (PolI), were constructed. The resulting strains were then transformed with the pCDF Cas1/Cas2 plasmid. Oligoelectroporation experiments were performed with naive adaptation induced by the addition of arabinose and IPTG. High-throughput sequencing was performed using the MiniSeq™ Sequencing System (Illumina, San Diego, CA, USA). Results. Here we determined that DNA polymerase I likely removes extra nucleotide at the 5' ends of spacer precursors, thereby allowing spacer precursors with extended 5' ends to be inserted into a CRISPR cassette as spacers. Conclusion. The knowledge gained significantly expands the understanding of the process of CRISPR adaptation. It is of fundamental and practical significance and opens up new opportunities in the understanding and application of CRISPR-Cas systems, for instance, aiding the development of new methods to combat infectious and other diseases.
- 8 December 2025
- Published by Ob'edinennaya Redakcya OOO in Molecular Genetics Microbiology and Virology (Russian version)
- Vol. 43 (4) , 74-78
The role of intracellular nucleases in the correction of aberrant 5’-ends of prespacers in the E. Coli CRISPR-Cas I-E system
Introduction. Bacteria need CRISPR-Cas systems to form an adaptive immune response necessary for protection against infectious agents. In addition, in recent years, CRISPR-Cas systems have been actively studied in the context of the development of new methods for editing the genome, which have great potential in the development of new strategies in the fight against infectious and other diseases. The mechanism of formation of bacterial adaptive immunity using CRISPR-Cas systems is in the ability of bacteria to integrate fragments of foreign DNA (for example, bacteriophage DNA), which are called spacers, into their genome, which further allows bacteria to recognize and protect themselves from these infectious agents. However, not much is known about the molecular mechanisms of this process, which limits a lot the ability of scientists to understand and apply CRISPR-Cas systems. In particular, the question of the role of non-CRISPR-Cas components of bacterial cells in the formation of CRISPR adaptation remains open. Such components, for example, are intracellular nucleases, which play a role in the CRISPR adaptation process we aimed to study within our scientific project. It has been previously proven that nucleases are involved in the preparation of a foreign DNA fragment for insertion into the bacterial DNA (CRISPR cassette), which is necessary to ensure CRISPR adaptation –it has to have the certain structure and the correct length. It has been shown that aberrations in the formation of the 5' ends of prespacers do not affect their incorporation into the CRISPR cassette and the efficiency of adaptation. Material and methods. Two mutant strains, Bl21-AI Δxni (Flap endonuclease ExoIX) and Bl21-AI ΔpolA exo (PolI), were constructed. The resulting strains were then transformed with the pCDF Cas1/Cas2 plasmid. Oligoelectroporation experiments were performed with naive adaptation induced by the addition of arabinose and IPTG. High-throughput sequencing was performed using the MiniSeq™ Sequencing System (Illumina, San Diego, CA, USA). Results. Here we determined that DNA polymerase I likely removes extra nucleotide at the 5' ends of spacer precursors, thereby allowing spacer precursors with extended 5' ends to be inserted into a CRISPR cassette as spacers. Conclusion. The knowledge gained significantly expands the understanding of the process of CRISPR adaptation. It is of fundamental and practical significance and opens up new opportunities in the understanding and application of CRISPR-Cas systems, for instance, aiding the development of new methods to combat infectious and other diseases.
- 1 December 2025
- Published by Allerton Press in Molecular Genetics, Microbiology and Virology
- Vol. 40 (S1) , S77-S85
Studying the Mechanisms of Prespacer 3'-End Formation during CRISPR Adaptation via Simultaneous Gene Repression Using dCas9
Introduction. Bacteria are capable of integrating a portion of the genetic material of an invading infectious agent as a spacer into the CRISPR array. This
- 1 December 2025
- Published by Allerton Press in Molecular Genetics, Microbiology and Virology
- Vol. 40 (S1) , S77-S85
Studying the Mechanisms of Prespacer 3'-End Formation during CRISPR Adaptation via Simultaneous Gene Repression Using dCas9
Introduction. Bacteria are capable of integrating a portion of the genetic material of an invading infectious agent as a spacer into the CRISPR array. This
- 1 December 2025
- Published by Allerton Press in Molecular Genetics, Microbiology and Virology
- Vol. 40 (S1) , S73-S76
The Role of Intracellular Nucleases in the Correction of Aberrant 5'-Ends of Prespacers in the E. coli CRISPR-Cas I-E System
Introduction. Bacteria need CRISPR-Cas systems to form an adaptive immune response necessary for protection against infectious agents. In addition, in rece
- 1 December 2025
- Published by Allerton Press in Molecular Genetics, Microbiology and Virology
- Vol. 40 (S1) , S73-S76
The Role of Intracellular Nucleases in the Correction of Aberrant 5'-Ends of Prespacers in the E. coli CRISPR-Cas I-E System
Introduction. Bacteria need CRISPR-Cas systems to form an adaptive immune response necessary for protection against infectious agents. In addition, in rece
- Open Access
- 21 September 2025
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 13 (9) , e012216
ESPEC-SUIT: a versatile and robust platform to identify and track antigen-specific T cell receptors in patients with cancer
Background: Methods to identify and characterize antigen-reactive T cell receptors (TCRs) represent important tools to understand and exploit T cell responses in patients with cancer and beyond. Current methods are hampered by the rarity of individual T cell clones and limited applicability to monitor both major histocompatibility complex (MHC) class I-restricted and MHC class II-restricted responses, hence insufficiently reflecting the entire antigen-reactive repertoire of a patient. To obtain broad and deep insight into polyclonal, antigen-specific TCR repertoires, we developed the ‘epitope-specific expansion culture with subsequent identification of TCRs’ (ESPEC-SUIT) assay to identify and track antigen-specific TCRs. Methods: In vitro stimulation of peripheral blood mononuclear cells with (vaccine-targeted) neoantigens was verified in cytokine secretion assays and read-out by TCRβ repertoire sequencing (TCRseq). Candidate antigen-reactive clonotypes were defined by specific expansion in cultures stimulated with relevant antigen, followed by TCR cloning and validation in co-cultures of TCR transgenic effector cells and peptide-presenting targets. Using TCRseq information, candidate and validated clonotypes were traced and characterized in bulk and single-cell repertoire sequencing data of longitudinally collected blood samples and tumor tissue. Results: In a cohort of 32 patients with cancer, we demonstrate that ESPEC-SUIT supports strong, robust and reproducible expansion of CD4 + and CD8 + T cells in response to various antigens. TCRseq revealed highly polyclonal neoepitope-specific T cell responses, which can be further characterized with respect to cross-reactivity, affinity or human leukocyte antigen (HLA) restriction. In a subcohort of 10 patients, we selected 341 ESPEC-SUIT-derived TCRs for cloning and in vitro functional validation from >2000 candidates and confirmed antigen-reactivity for >75%. We exemplify the usefulness of this TCR discovery method for downstream analysis in neoepitope vaccinated patients with glioma, where we found longitudinal changes in candidate TCR frequencies in blood mirroring antigen-specific ex vivo Enzyme-Linked ImmunoSpot (ELISpot) responses. Furthermore, up to 67% of candidates could be detected in on-treatment brain tumor tissue and exhibited gene expression signatures overlapping with clonotypes of confirmed specificity to the vaccine antigen. Conclusion: ESPEC-SUIT provides unprecedented insight into highly polyclonal, antigen-specific T cell responses and enables discovery of large numbers of TCRs for a given antigen. It represents an efficient, cost-effective and scalable framework for the interrogation of tumor-reactive T cell responses in patients with cancer.
- 21 September 2025
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 13 (9) , e012216
Open AccessESPEC-SUIT: a versatile and robust platform to identify and track antigen-specific T cell receptors in patients with cancer
Background: Methods to identify and characterize antigen-reactive T cell receptors (TCRs) represent important tools to understand and exploit T cell responses in patients with cancer and beyond. Current methods are hampered by the rarity of individual T cell clones and limited applicability to monitor both major histocompatibility complex (MHC) class I-restricted and MHC class II-restricted responses, hence insufficiently reflecting the entire antigen-reactive repertoire of a patient. To obtain broad and deep insight into polyclonal, antigen-specific TCR repertoires, we developed the ‘epitope-specific expansion culture with subsequent identification of TCRs’ (ESPEC-SUIT) assay to identify and track antigen-specific TCRs. Methods: In vitro stimulation of peripheral blood mononuclear cells with (vaccine-targeted) neoantigens was verified in cytokine secretion assays and read-out by TCRβ repertoire sequencing (TCRseq). Candidate antigen-reactive clonotypes were defined by specific expansion in cultures stimulated with relevant antigen, followed by TCR cloning and validation in co-cultures of TCR transgenic effector cells and peptide-presenting targets. Using TCRseq information, candidate and validated clonotypes were traced and characterized in bulk and single-cell repertoire sequencing data of longitudinally collected blood samples and tumor tissue. Results: In a cohort of 32 patients with cancer, we demonstrate that ESPEC-SUIT supports strong, robust and reproducible expansion of CD4 + and CD8 + T cells in response to various antigens. TCRseq revealed highly polyclonal neoepitope-specific T cell responses, which can be further characterized with respect to cross-reactivity, affinity or human leukocyte antigen (HLA) restriction. In a subcohort of 10 patients, we selected 341 ESPEC-SUIT-derived TCRs for cloning and in vitro functional validation from >2000 candidates and confirmed antigen-reactivity for >75%. We exemplify the usefulness of this TCR discovery method for downstream analysis in neoepitope vaccinated patients with glioma, where we found longitudinal changes in candidate TCR frequencies in blood mirroring antigen-specific ex vivo Enzyme-Linked ImmunoSpot (ELISpot) responses. Furthermore, up to 67% of candidates could be detected in on-treatment brain tumor tissue and exhibited gene expression signatures overlapping with clonotypes of confirmed specificity to the vaccine antigen. Conclusion: ESPEC-SUIT provides unprecedented insight into highly polyclonal, antigen-specific T cell responses and enables discovery of large numbers of TCRs for a given antigen. It represents an efficient, cost-effective and scalable framework for the interrogation of tumor-reactive T cell responses in patients with cancer.